Growth Metrics

Oruka Therapeutics (ORKA) Current Deferred Revenue (2010 - 2013)

Oruka Therapeutics' quarterly Current Deferred Revenue came in at $3000.0 in Q2 2013, down 90.91% year-on-year from $33000.0 in Q2 2012, and down 62.5% quarter-over-quarter from $8000.0 in Q1 2013.

Oruka Therapeutics has reported Current Deferred Revenue for 4 years, with the latest figure at $3000.0 in Q2 2013.

  • For the quarter ending Q2 2013, Current Deferred Revenue fell 90.91% year-over-year to $3000.0; the trailing twelve-month figure through Jun 2013 stood at $3000.0 (down 90.91% YoY), and the FY2012 full-year result was $16000.0, down 51.52% from the prior year.
  • Current Deferred Revenue for Q2 2013 stood at $3000.0, down from $8000.0 in the prior quarter.
  • The five-year high for Current Deferred Revenue was $121000.0 in Q4 2010, with the low at $3000.0 in Q2 2013.
  • Average Current Deferred Revenue over 4 years is $33600.0, with a median of $32500.0 recorded in 2011.
  • Year-over-year, Current Deferred Revenue changed 0.0% in 2012 and plunged 90.91% in 2013.
  • Tracing ORKA's Current Deferred Revenue over 4 years: stood at $121000.0 in 2010, then slumped by 72.73% to $33000.0 in 2011, then tumbled by 51.52% to $16000.0 in 2012, then plunged by 81.25% to $3000.0 in 2013.
  • The last three Current Deferred Revenue figures came in at $3000.0 (Q2 2013), $8000.0 (Q1 2013), and $16000.0 (Q4 2012), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Oruka Therapeutics 3.04 Bn 2.65 Bn -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2013 3,000.00
Mar 31, 2013 8,000.00
Dec 31, 2012 16,000.00
Sep 30, 2012 24,000.00
Jun 30, 2012 33,000.00
Mar 31, 2012 33,000.00
Dec 31, 2011 33,000.00
Sep 30, 2011 32,000.00
Jun 30, 2011 33,000.00
Dec 31, 2010 121,000.00